GCA1003

GCA1003 is a small molecule therapeutic candidate being developed by Guangzhou Green Cross Pharmaceutical for the treatment of presbyopia. Classified as a Class 1 chemical drug in China, it represents a new molecular entity. The program is currently in the preclinical stage, specifically undergoing Chemistry, Manufacturing, and Controls (CMC) development. Presbyopia is an age-related condition characterized by the gradual loss of the eye's ability to focus on nearby objects, typically due to the hardening of the crystalline lens. While the specific mechanism of action for GCA1003 has not been publicly disclosed, pharmacological treatments for presbyopia generally aim to either increase the depth of field through pupillary constriction (miotics) or restore lens elasticity by reducing protein cross-linking.